Sildenafil Tablet, Film Coated
Product Images NDC 59746-471

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 59746-471). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000s (1000s Label)

Sildenafil Tablets, USP 20 mg film-coated tablets packaging label. The label indicates a bottle containing 1000 tablets, manufactured by Jubilant Generics Limited, India, and marketed by Jubilant Cadista Pharmaceuticals Inc., USA. Storage instructions and usual dosage advisories are included, along with barcode, NDC 59746-471-10, and variable batch details placeholder.*

FDA Label Image

500s (500s Label)

Label for Sildenafil Tablets USP 20 mg film-coated tablets, marketed by Jubilant Cadista Pharmaceuticals Inc. The label indicates a bottle size of 500 tablets and specifies storage temperature instructions and manufacturing information. The product is prescription-only and includes barcode and variable batch details section.*

FDA Label Image

Container (Container)

Label for Sildenafil Tablets, USP, 20 mg film-coated tablets, supplied in a package containing 90 tablets. The label includes storage instructions, manufacturer Jubilant Generics Limited in India, and marketing by Jubilant Cadista Pharmaceuticals Inc., USA. It features the NDC 59746-471-90 and includes barcode and serial data.*

FDA Label Image

Fig-1 (Fig 1)

A chart showing the fold change and 90% confidence interval of area under the curve (AUC) and maximum concentration (Cmax) for various interacting drugs relative to sildenafil alone. It includes drugs such as Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, oral contraceptives, Ritonavir, and Saquinavir. The chart provides dosing recommendations, indicating whether dose adjustment or coadministration is advised.*

FDA Label Image

Fig08 (Fig08)

A dot plot chart showing the fold change and 90% confidence intervals (CI) for various pharmacokinetic parameters (INR, AUC, Cmax, BT) of Sildenafil when coadministered with different interacting drugs. The chart compares changes relative to the interacting drug alone and provides dosing recommendations, mostly indicating 'No dose adjustment' except for ritonavir where 'Coadministration not recommended' is noted. Additional footnotes explain specific details about doses and effects.*

FDA Label Image

Fig09 (Fig09)

A line graph showing changes from baseline in meters over 12 weeks of study. The x-axis denotes the study weeks (4, 8, 12) and the y-axis indicates change in meters, ranging from -20 to 80. Four groups are represented: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, each with plotted points and error bars indicating variability.*

FDA Label Image

Fig10 (Fig10)

A forest plot chart showing placebo-corrected changes in 6-minute walk distance for Sildenafil 20 mg taken three times daily (TID). The chart breaks data down by baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary arterial pressure (PAP), and pulmonary vascular resistance index (PVRI), with values representing treatment effects and confidence intervals across subgroups.*

FDA Label Image

Fig11 (Fig11)

A line graph depicting the percentage of subjects without a clinically worsening event over time (days from randomization) comparing Sildenafil and Placebo groups. The x-axis shows days from 0 to 112, and the y-axis shows the percentage from 0 to 100. Two lines represent the data: a dashed line for Sildenafil and a solid line for Placebo, with Sildenafil maintaining a higher percentage throughout the period.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of sildenafil, the active ingredient in the product. The image shows molecular bonds and functional groups characteristic of sildenafil citrate, including heterocyclic rings and side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.